German radiopharmaceutical firm ITM Isotopen Technologies Munich has received an investment of 20 million euros from Medtech Focused Family Office.
ITM plans to use the funds to advance the development of its proprietary line of targeted radionuclide therapies, accelerate to market its therapeutic and diagnostic products, and enhance the company's growth.
